Evidence map›Paper›PMID 40782343›Full record

ArticleCancer2025

Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.

Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Sanam Loghavi, Ghayas C Issa, Nicholas J Short, Tapan M Kadia, Courtney D DiNardo and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sankalp AroraDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8162-4119
Wei-Ying JenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Musa YilmazDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Indraneel DeshmukhDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jayastu SenapatiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6831-2567
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2983-2738
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9892-9832
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9003-0390
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joseph JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1670-6513
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8027-9659
Kapil BhallaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Uday PopatDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7592-2224
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Betul OranDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1264-5968
Hussein A AbbasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-3631-2482
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-7103-373X

Funding

The University of Texas MD Anderson Cancer Center CA016672The University of Texas MD Anderson Cancer Center Leukemia Specialized Programs of Research Excellence CA1100632
6 · The paper itself

Abstract

backgroundThe prognostic impact of Fms-like tyrosine kinase 3 (FLT3)-tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with FLT3-TKD mutated (FLT3-TKD

methodsThis retrospective study included patients with newly diagnosed AML who received frontline treatment at The University of Texas MD Anderson Cancer Center from January 2012 to March 2024 divided into two cohorts: FLT3-TKD

resultsIn total, 2922 patients were screened, and 250 met inclusion criteria, including 124 patients with FLT3-TKD

conclusionsFLT3-TKD

Indexed as

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationNuclear ProteinsAdolescentAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedNucleophosminPrognosisRetrospective StudiesYoung AdultFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiaallogeneic stem cell transplantationFLT3‐tyrosine kinase domain (TKD) mutationFms‐like tyrosine kinase 3 (FLT3) inhibitorsnucleophosmin (NPM1) mutationvenetoclax

Identifiers

PMID40782343
PMCPMC12335293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.